AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 2:37 PM ET RBC Capital lifts GRAIL price target to $100 from $84 AI-generated summary · Source: press report
U.S. listed: $GRALCancer screening and diagnosticsExecution and funding risks

GRAL Stock Hub: GRAIL News, Cancer Screening and Galleri

GRAIL reported Q3 revenue of $37.5 million, including $37.3 million from Galleri. September 30 liquidity was $788.7 million. GRAIL anticipates an FDA decision on Galleri by early Q1 2027.

Last updated: November 11, 2026Financial period: quarter and nine months ended September 30, 2026Market reference: November 4 completed regular-session close, before Q3 releaseCurrency: USD
Full research report · PDF
GRAIL research updated November 5, 2026
20 pages. Q3 financial results, Galleri clinical evidence, the FDA advisory votes, liquidity and dilution. Personal use only: redistribution prohibited.
Get the report (PDF)
Next company milestone
By early Q1 2027 · FDA decision on Galleri

A management presentation at the UBS Global Healthcare Conference in Palm Beach, Florida, was set for November 10, and Q3 results were released on November 4. The company anticipates an FDA decision on Galleri by early Q1 2027; that is a company expectation, not a fixed FDA action date. UBS presentation announcement; Q3 2026 results

Company-guided windows remain forecasts; completed events are dated separately from the next operating or financial disclosure.
GRAIL GRAL daily stock chart
Daily chart $GRAL. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

GRAL stock at a glance

Close · November 4, 2026
$143.66
U.S. regular session, before the Q3 release. +3.03% from the prior close. USD.
Price series in PDF, page 2
Cash and equivalents
$28.976M
September 30, 2026
Source
Short-term securities
$759.700M
September 30, 2026
Source
Total liquidity
$788.676M
September 30, 2026. Cash and short-term securities.
Source
Q3 total revenue
$37.535M
Quarter ended September 30, 2026. Up 4% year over year.
Source
Galleri revenue
$37.269M
Q3 2026. Up 14% year over year.
Source
Common shares
44.962M
Outstanding on November 2, 2026 (Form 10-Q cover); 44.753M at September 30.
Source
Q3 GAAP net loss
$103.568M
Quarter ended September 30, 2026. $88.977M a year earlier.
Source

Where GRAIL stands now

GRAIL reported Q3 revenue of $37.5 million, including $37.3 million from Galleri. September 30 liquidity was $788.7 million. GRAIL anticipates an FDA decision on Galleri by early Q1 2027. On September 23, 2026, the FDA advisory panel voted on Galleri for the proposed screening population of adults aged 50 and older. On whether the data reasonably supported safety, the vote was 10 yes, 0 no and 0 abstentions. On effectiveness, it was 6 yes, 4 no and 0 abstentions. On whether benefits outweighed risks, it was 7 yes, 2 no and 1 abstention. FDA makes the final decision. FDA voting summary.

Q3 total revenue was $37.535 million versus $36.194 million a year earlier. Galleri revenue was $37.269 million, up 14%, on more than 56,000 tests, up approximately 24%. Development services contributed $0.266 million. Nine-month revenue was $123.007 million versus $103.575 million, including $119.743 million of Galleri revenue, up 24%, on more than 174,000 tests, up 36%. GAAP net loss was $103.568 million for Q3 and $307.002 million for nine months. GAAP Q3 gross loss was $18.111 million. Q3 income statement.

Execution and funding. The NHS combined stage III/IV primary endpoint was missed. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]

The constructive case

A favorable final label, manageable study obligations, growing repeat use and meaningful coverage could turn an already commercial screening platform into a larger recurring business. Liquidity of $788.7 million at September 30 gives GRAIL resources to pursue that transition. Approval, reimbursement and cash generation remain separate milestones.

The cautious case

The NHS combined stage III/IV primary endpoint was missed. In Q3 2026 the net loss widened to $103.6 million from $89.0 million a year earlier, and adjusted gross margin fell to 42% from 55%. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]

Latest GRAIL news

Nov 5, 2026

RBC Capital lifts GRAIL price target to $100 from $84

RBC Capital raised its price target on GRAIL to $100 from $84. The bank kept its Sector Perform rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 4, 2026

GRAIL Reports Third Quarter 2026 Financial Results

Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test volume grew approximately 24% year-over-year to more than 56,000 tests. Net loss for the third quarter was $103.6 million, and non-GAAP adjusted EBITDA was $(92.6) million. Cash, cash equivalents, and short-term marketable securities totaled $788.7 million as of September 30, 2026.

Nov 3, 2026

Chancery court ends Icahn lawsuit over Illumina's $8B acquisition of Grail

A Chancery court has ended the lawsuit brought by Icahn over Illumina's $8B deal for Grail. The source gives no further details. Not confirmed by a company release or filing at the time of writing; to be verified.

Nov 3, 2026

FDA panel backs GRAIL's cancer detection test

An FDA panel backed GRAIL's cancer detection test. No further details are given in the available headline. Not confirmed by a company release or filing at the time of writing; to be verified.

Oct 27, 2026

UBS conference scheduled for November 10

The company calendar lists the UBS Global Healthcare Conference on November 10 at 11:00 am ET. This is a scheduled investor event, separate from the November 4 financial results and from any final FDA decision.

Oct 21, 2026

Q3 results date set for November 4

GRAIL will report third-quarter 2026 results after the market close on Wednesday, November 4, 2026, followed by a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET.

GRAL stock catalysts and company milestones

  • October 27 PATHFINDER 2 subgroup analysis Completed
  • October 26 ESMO PATHFINDER 2 Completed
  • October 25 ESMO claims analysis Completed
  • November 4, 2026 — Q3 2026 results released after the close (total revenue $37.5 million, net loss $103.6 million), followed by a 4:30 pm ET call. Completed
  • November 10, 2026 · 11:00 am ET — Presentation at the UBS Global Healthcare Conference in Palm Beach, Florida, was set for this date. Company-announced event
  • By early Q1 2027 — FDA decision on Galleri anticipated by the company. Company expectation; no fixed FDA action date

Q3 2026 results; UBS presentation announcement; Company event calendar

Business model: a screening service with a long evidence cycle

GRAIL, Inc. is a cancer-detection company listed on Nasdaq under GRAL. Its central commercial asset is Galleri, a prescription blood test designed to look for a cancer-associated signal across multiple cancer types and, when a signal is detected, indicate a likely anatomical origin. The company’s September and October 2026 communications identify Sunnyvale, California, as its headquarters. The June-quarter 10-Q cover still shows Menlo Park, although the filing notes that the new Sunnyvale headquarters became available on June 1, 2026. The product is a screening service, not a cancer treatment and not a definitive diagnosis. [FDA] [Q] [O]

The business can be understood as a sequence of linked transactions. A healthcare professional orders a test; a sample is collected and shipped; GRAIL processes it and delivers a result; a positive result requires a diagnostic pathway outside the assay itself. Revenue from the screening test therefore measures only one part of the wider healthcare intervention. The laboratory’s commercial success depends on whether patients, clinicians and payers find the entire pathway useful enough to repeat and fund.

Primary source

Financial statements: liquidity is not profitability

At June 30, 2026, GRAIL reported $55.645 million in cash and cash equivalents and $805.964 million in short-term marketable securities. Their sum is $861.609 million. Restricted cash of $6.974 million is separate and is not added to the readily available liquidity figure shown above. These figures are dated June 30. [Q]

For Q2, the company reported an operating loss of $173.783 million and a net loss of $110.247 million. GAAP gross loss was $12.566 million. Adjusted gross profit of $21.555 million excludes specified items, including amortization and allocated stock compensation, and is therefore not the same metric. Adjusted EBITDA was negative $90.270 million. Presenting the adjusted gross figure without the GAAP loss would make the business look more mature than its reported accounts. [Q]

Primary source

Q3 total revenue was $37.535 million versus $36.194 million a year earlier. Galleri revenue was $37.269 million, up 14%, on more than 56,000 tests, up approximately 24%. Development services contributed $0.266 million. Nine-month revenue was $123.007 million versus $103.575 million, including $119.743 million of Galleri revenue, up 24%, on more than 174,000 tests, up 36%. GAAP net loss was $103.568 million for Q3 and $307.002 million for nine months. GAAP Q3 gross loss was $18.111 million. Q3 income statement.

Q3 adjusted gross profit was $15.914 million and adjusted gross margin was 42%, versus $20.011 million and 55% a year earlier. GRAIL excludes intangible amortization and stock-based compensation allocated to cost of revenue. Adjusted EBITDA was a loss of $92.580 million versus $71.704 million a year earlier. GRAIL adjusts net loss for intangible amortization, stock compensation, depreciation, impairment, income tax benefit, interest income and restructuring. Company reconciliations.

At September 30, 2026, cash and equivalents were $28.976 million and short-term marketable securities were $759.700 million, for $788.676 million in combined liquidity. Restricted cash of $6.943 million was separate. The condensed balance sheet listed $85.848 million in current and non-current operating lease liabilities and showed no separate debt or convertible-debt line. Q3 balance sheet.

The Form 10-Q filed on November 5 covers the first nine months of 2026: net cash used in operating activities was $242.459 million, against $235.222 million a year earlier, and financing activities provided $113.981 million, mainly the $109.0 million of net proceeds from the June Samsung share purchase. GRAIL states that existing cash, cash equivalents and short-term marketable securities, together with the anticipated commercial adoption of Galleri, will be sufficient for at least the next 12 months from the filing date. Q3 2026 Form 10-Q and November 4 Q3 release.

GRAIL reported 44,753,179 common shares issued and outstanding on September 30 in its Q3 balance sheet, compared with 44,666,234 at June 30 and 40,331,360 at December 31, 2025; the Form 10-Q cover reports 44,962,171 shares on November 2, 2026. At September 30, $189.3 million of shares remained available under the ATM program, unchanged from June 30. Available capacity can fund operations through new share issuance and can dilute existing ownership. September balance sheet and Q3 2026 Form 10-Q.

Merlintrader Health Score · $GRAL

3.10out of 5
Balance sheet / runway · 30%3.5

September 30 liquidity of $788.7 million supports operations. Nine-month operating cash use of $242.5 million and the wider Q3 net loss point to continued funding needs; the 10-Q states a funding horizon of at least 12 months.

Catalysts · 30%3.0

The September panel supported Galleri on all three questions. FDA action, final labeling and coverage remain unresolved, and NHS-Galleri missed its primary endpoint.

Dilution · 20%2.5

Common shares outstanding were 44.8 million at September 30 and 44.96 million on November 2, up from 40.3 million at December 31. $189.3 million of ATM capacity remained at September 30, alongside equity awards.

Trading liquidity · 10%3.5

TWS recorded 273,700 shares of regular-session volume at the November 4 close of $143.66. Executable depth can change around regulatory news.

Execution · 10%3.0

Galleri revenue grew 14% in Q3, with test volume up about 24%. Adjusted gross margin fell to 42% from 55% a year earlier.

Reassessed November 5, 2026, including the Form 10-Q filed that day; scores unchanged. Weighted calculation: (3.5 × 30%) + (3.0 × 30%) + (2.5 × 20%) + (3.5 × 10%) + (3.0 × 10%) = 3.10 / 5. Financial and operating resilience over twelve to eighteen months; no price target or investment recommendation.

Red flags

  • The NHS combined stage III/IV primary endpoint was missed. A restrictive or delayed regulatory outcome, weak repeat adoption or persistent cash consumption could outweigh the favorable panel vote. A large cash balance does not guarantee per-share value or prevent further dilution. [FDA] [Q]
  • Company forecasts depend on execution and may change.
  • Financing after September 30 would change liquidity and could increase the share count.
  • Investment involves possible loss of part or all of the capital.

GRAL Stock FAQ: GRAIL Questions Answered

What is the next GRAL stock catalyst?

As of November 11, 2026, GRAIL’s next catalyst is the FDA decision on Galleri, which the company anticipates by early Q1 2027; that is a company expectation, not a fixed FDA action date. A presentation at the UBS Global Healthcare Conference was set for November 10, 2026. GRAIL released Q3 results after the November 4 regular-session close. The FDA has the final decision. Q3 release and Company event announcement.

Is the GRAIL Galleri test FDA approved?

The FDA decision on Galleri was pending as of November 5, 2026. On September 23, 2026, the FDA advisory panel voted on Galleri for the proposed screening population of adults aged 50 and older. On whether the data reasonably supported safety, the vote was 10 yes, 0 no and 0 abstentions. On effectiveness, it was 6 yes, 4 no and 0 abstentions. On whether benefits outweighed risks, it was 7 yes, 2 no and 1 abstention. FDA makes the final decision. FDA voting summary.

How much cash does GRAIL have?

GRAIL held $788.676 million in cash, cash equivalents and short-term marketable securities at September 30, 2026, down from $861.609 million at June 30, 2026. September balance sheet. June balance sheet and cash flows.

Could GRAIL issue more GRAL shares?

GRAIL could issue more shares under the ATM program, which had $189.3 million of capacity remaining at June 30, 2026. Common shares outstanding increased to 44,753,179 at September 30 from 44,666,234 at June 30. June Form 10-Q and September balance sheet.

When does GRAIL next report earnings?

As of November 11, 2026, GRAIL has not announced its next earnings date. On November 4, 2026, it reported $37.5 million in Q3 revenue and a $103.6 million GAAP net loss after the close. Galleri revenue grew 14% year over year to $37.3 million on more than 56,000 tests. Q3 financial results.

What does GRAIL do?

As of November 4, 2026, GRAIL sold a prescription blood test that screens for cancer signals. Galleri looks for cancer-associated DNA methylation and can suggest where to investigate a detected signal. Company description and Galleri information.

Did the GRAIL NHS-Galleri trial meet its primary endpoint?

The NHS-Galleri trial missed its combined stage III and IV primary endpoint, as reported on May 30, 2026. The published incidence rate ratio for stage IV alone after three screening rounds was 0.86, a key secondary result. Original NHS-Galleri trial.

Does a positive GRAIL Galleri result diagnose cancer?

The FDA advisory panel stated on September 23, 2026 that a positive Galleri test requires further diagnostic work to confirm cancer. A negative test cannot rule out cancer. The FDA panel advised patients to continue guideline-recommended screening. FDA panel summary.

Primary sources

Disclaimer. Educational and informational commentary only. This is not investment advice or a recommendation to buy, sell or hold a security. AI-assisted analysis uses dated primary disclosures; errors remain possible and company forecasts are not guarantees. Verify material facts in the sources.

Cancer-screening studies, regulatory decisions, diagnostic follow-up, reimbursement and financing carry risks. A test signal is not a cancer diagnosis, and a negative test does not exclude cancer or replace recommended screening. Investments may lose substantial value.

Full disclaimer and terms of use.